KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis

Surgical Oncology

Volumn 22, Issue 2, 2013, Pages 105-111

  Clancy, Cillian ^a   Burke, John P ^a   Coffey, J Calvin ^a,b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

KRAS; Pathological complete response; Radiotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; EMBASE; GENE MUTATION; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHEMORADIOTHERAPY; HUMANS; META-ANALYSIS AS TOPIC; MUTATION; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84878863305     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2013.02.001     Document Type: Review

References (42)

1. J.G. Kuremsky, J.E. Tepper, and H.L. McLeod Biomarkers for response to neoadjuvant chemoradiation for rectal cancer Int J Radiat Oncol Biol Phys 749 3 2009 673 688
2. C. Mao, R.Y. Liao, and L. Qiu BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis Mol Biol Rep 38 4 2011 2219 2223
3. D.Z. Chang, V. Kumar, and Y. Ma Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy J Hematol Oncol 2 2009 18
4. D. Soulières, W. Greer, and A.M. Magliocco KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies Curr Oncol 17 Suppl. 1 2010 S31 S40
5. W. De Roock, H. Piessevaux, and J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 3 2008 508 515
6. F. Di Fiore, F. Blanchard, and F. Charbonnier Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 8 2007 1166 1169
7. Alberici P. The adenoma-carcinoma sequence in colorectal cancer: scratching the surface (Doctoral Thesis); 2007-04-20 repub.eur.nl/res/aut/12453/ .
8. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trial 7 1986 177 188
9. C. Dunne, J.P. Burke, and M. Morrow Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ J Clin Oncol 27 10 2009 1615 1620
10. J. Lau, J.P. Ioannidis, and C.H. Schmid Quantitative synthesis in systematic reviews Ann Intern Med 127 9 1997 820 826
11. W.G. McKenna, M.C. Weiss, and V.J. Bakanauskas The role of the H-ras oncogene in radiation resistance and metastasis Int J Radiat Oncol Biol Phys 18 4 1990 849 859
12. H.A. Jones, S.M. Hahn, and E. Bernhard Ras inhibitors and radiation therapy Sem Radiat Oncol 11 4 2001 328 337
13. E.J. Bernhard, E.J. Stanbridge, and S. Gupta Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines Cancer Res 60 23 2000 6597 6600
14. F. Stipa, D.B. Chessin, and J. Shia A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography Ann Surg Oncol 13 8 2006 1047 1053
15. V.K. Mehta, J. Poen, and J. Ford Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer Dis Colon Rectum 44 1 2001 52 58
16. J.S. Kim, J.S. Kim, and M.J. Cho Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 54 2 2002 403 408
17. J.G. Guillem, D.B. Chessin, and A.M. Cohen Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer Ann Surg 241 5 2005 829 836 [discussion 836-8]
18. J.F. Bosset, V. Magnin, and P. Maingon Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial Int J Radiat Oncol Biol Phys 46 2000 323 327
19. L.F. de Campos-Lobato, L. Stocchi, and A. da Luz Moreira Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers Ann Surg Oncol 17 2010 1758 1766
20. L.F. de Campos-Lobato, L. Stocchi, and A.L. Moreira Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence Ann Surg Oncol 18 6 2011 1590 1598
21. J. Gaedcke, M. Grade, and K. Jung KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 94 1 2010 76 81
22. G. Theodoropoulos, W.E. Wise, and A. Padmanabhan T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival Dis Colon Rectum 45 7 2002 895 903
23. J. Feliu, J. Calvilio, and A. Escribano Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy Ann Oncol 13 5 2002 730 736
24. C. Fernandez-Martos, J. Aparicio, and C. Bosch Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-up J Clin Oncol 22 15 2004 3016 3022
25. P.L. Sun, B. Li, and O.F. Ye Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study Int J Colorectal Dis 27 10 2012 1325 1332
26. F.M. Vecchio, V. Valentini, and B.D. Minsky The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer Int J Radiat Oncol Biol Phys 62 3 2005 752 760
27. J. Ioannidis, M. Gwinn, and J. Little A road map for efficient and reliable human genome epidemiology Nat Genet 38 1 2006 3 5
28. J. Little, J.P. Higgins, and J. Ioannidis STrengthening the REporting of Genetic Association Studies (STREGA)-an extension of the STROBE statement Eur J Clin Invest 39 4 2009 247 266
29. J.M. Davies, D. Trembath, A.M. Deal, and W.K. Funkhouser Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy Radiat Oncol 6 2011 114
30. S.Y. Kim, Y.S. Hong, and D.Y. Kim Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study Int J Radiat Oncol Biol Phys 81 3 2011 677 683
31. P. Erben, P. Ströbel, and K. Horisberger KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 81 4 2011 1032 1038
32. P. Grimminger, P. Danenberg, and K. Dellas Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer Clin Cancer Res 17 10 2011 3469 3477
33. S. Hu-Lieskovan, D. Vallbohmer, and W. Zhang EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients Clin Cancer Res 17 15 2011 5161 5169
34. J. Garcia-Aguilar, Z. Chen, and D. Smith Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer Ann Surg 254 3 2011 486 492 [discussion 492-3]
35. C. Bengala, S. Bettelli, and F. Bertolini Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy Br J Cancer 103 7 2010 1019 1024
36. S.T. Martin, H.M. Heneghan, and D.C. Winter Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer Br J Surg 99 7 2012 918 928
37. Y. Edden, S.D. Wexner, and M. Berho The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma Colorectal Dis 14 5 2012 555 561
38. D. Edler, U. Kressner, and P. Ragnhammar Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival Clin Cancer Res 6 2 2000 488 492
39. T. Yokota Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-cancer Agents Med Chem 12 2 2012 163 171
40. E. Bellon, M.J. Ligtenberg, S. Tejpar, and K. Cox External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds Oncologist 16 4 2011 467 478
41. W. De Roock, D.J. Jonker, F. Di Nicolantonio, and A. Sartore-Bianchi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 16 2010 1812 1820
42. S. Tejpar, I. Celik, M. Schlichting, and U. Sartorius Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 29 2012 3570 3577